spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  thyroid cancer 

 HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2019
CHMP Issues Positive Opinion to Expand Trulicity(R) (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Biopharmaceuticals Endocrinology Cardiology Regulatory
 HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Diagnostics Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 20 Aug 2018
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 May 2018
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 26 Feb 2018
New Data Show Lilly's Trulicity(R) (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2017
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2017
Veracyte Announces Executive Promotions
Diagnostics Oncology Personnel
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Oct 2016
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 6 Oct 2016
Interpace Diagnostics Launches New Streamlined Molecular Product for Pancreatic Cysts
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2016
Interpace Diagnostics Presents New Clinical Utility Data at Digestive Disease Week
Diagnostic Gastroenterology Oncology
 HSMN NewsFeed - 18 Apr 2016
Interpace Diagnostics Announces New Coding by Novitas Solutions for PancraGen(TM)
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 19 Feb 2016
Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma(R) Gene Expression Classifier in Thyroid Cancer Diagnosis
Diagnostics Oncology
 HSMN NewsFeed - 17 Feb 2016
Interpace Diagnostics Receives Medicare Coverage For Its ThyraMIR(TM) Micro RNA Gene Expression Classifer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 22 Jan 2016
Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma(R) Gene Expression Classifier
Diagnostics Oncology
 HSMN NewsFeed - 20 Jan 2016
Interpace Diagnostics Announces New Medicare Local Coverage Determination for Molecular Testing of Pancreatic Cysts
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 12 Jan 2016
Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp
Diagnostics Oncology
 HSMN NewsFeed - 12 Nov 2015
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 17 Aug 2015
Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 22 Jul 2015
AstraZeneca Provides Update On Selumetinib In Uveal Melanoma
Biopharmaceuticals Oncology Ophthalmology
 HSMN NewsFeed - 11 Mar 2015
Pathway Genomics Appoints Former Cedars-Sinai Chair of Medicine Glenn D. Braunstein, M.D., as Chief Medical Officer
Diagnostics Personnel
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2014
Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice President of Sales and Marketing
Diagnostics Personnel
 HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jun 2014
Navidea Biopharmaceuticals’ Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2014
Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
Biopharmaceuticals Radiology Distribution
 HSMN NewsFeed - 10 Dec 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek(R) for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 12 Apr 2013
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
Diagnostics Personnel
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2012
FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases
Devices Oncology FDA
 HSMN NewsFeed - 5 Apr 2012
Richard T. Kloos, M.D., Joins Veracyte as Senior Medical Director
Diagnostics Personnel
 HSMN NewsFeed - 20 Jan 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Diagnostics Endocrinology Oncology Personalized Medicine
 HSMN NewsFeed - 25 Oct 2011
Exelixis Appoints Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2011
Novo Nordisk Announces U.S. Launch of NovoTwist(R) for Use with Levemir(R) FlexPen(R), NovoLog(R) FlexPen(R) and Victoza(R) Pen Devices
Devices Drug Delivery Endocrinology
 HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2010
US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2010
Eighth CyberKnife System in South Korea Installed and Treating Patients
Devices Oncology
 HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2010
Veracyte Completes $28 Million Series B Round - One Step Closer to Commercializing First Molecular Diagnostic Product
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 11 Feb 2010
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2009
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2009
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 6 Feb 2009
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2008
OXiGENE, Inc. Names John A. Kollins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Dec 2007
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2007
AkaRx and MGI PHARMA Announce Closing of Development and License Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Aug 2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jun 2007
Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
PET/CT: The Best Test for Women With Ovarian Cancer
Devices Radiology Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
OXiGENE Reaches Agreement with FDA on Special Protocol Assessment for ZYBRESTAT(TM) (CA4P) Phase II/III Pivotal Trial in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
NCCN Updates Thyroid Carcinoma Guidelines
Oncology
 HSMN NewsFeed - 5 Apr 2007
New Device from LED Dental May Allow Earlier Detection of Oral Cancer
Devices Diagnostics Oncology Dental
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Nov 2006
AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2006
U.S. FDA Grants Orphan Drug Designation to OXiGENE's Lead Clinical Candidate, Combretastatin A4P (CA4P), for the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
thyroid cancer
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.